全文获取类型
收费全文 | 54636篇 |
免费 | 3647篇 |
国内免费 | 1155篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 1237篇 |
妇产科学 | 686篇 |
基础医学 | 2795篇 |
口腔科学 | 611篇 |
临床医学 | 7560篇 |
内科学 | 18399篇 |
皮肤病学 | 170篇 |
神经病学 | 940篇 |
特种医学 | 947篇 |
外国民族医学 | 1篇 |
外科学 | 6742篇 |
综合类 | 8549篇 |
现状与发展 | 3篇 |
预防医学 | 2330篇 |
眼科学 | 86篇 |
药学 | 4893篇 |
46篇 | |
中国医学 | 2730篇 |
肿瘤学 | 613篇 |
出版年
2024年 | 96篇 |
2023年 | 883篇 |
2022年 | 1544篇 |
2021年 | 2300篇 |
2020年 | 2200篇 |
2019年 | 1956篇 |
2018年 | 1919篇 |
2017年 | 1736篇 |
2016年 | 1777篇 |
2015年 | 1837篇 |
2014年 | 3900篇 |
2013年 | 4177篇 |
2012年 | 3038篇 |
2011年 | 3583篇 |
2010年 | 2801篇 |
2009年 | 2835篇 |
2008年 | 2761篇 |
2007年 | 2777篇 |
2006年 | 2460篇 |
2005年 | 2287篇 |
2004年 | 1761篇 |
2003年 | 1477篇 |
2002年 | 1240篇 |
2001年 | 1151篇 |
2000年 | 856篇 |
1999年 | 735篇 |
1998年 | 600篇 |
1997年 | 545篇 |
1996年 | 536篇 |
1995年 | 460篇 |
1994年 | 445篇 |
1993年 | 332篇 |
1992年 | 293篇 |
1991年 | 288篇 |
1990年 | 252篇 |
1989年 | 251篇 |
1988年 | 232篇 |
1987年 | 171篇 |
1986年 | 146篇 |
1985年 | 145篇 |
1984年 | 121篇 |
1983年 | 69篇 |
1982年 | 81篇 |
1981年 | 76篇 |
1980年 | 63篇 |
1979年 | 66篇 |
1978年 | 50篇 |
1977年 | 31篇 |
1976年 | 39篇 |
1974年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
35.
36.
37.
38.
39.
《Annals of hepatology》2019,18(3):514-516
Gyromitra esculenta, also known as “false morel” is one of the most poisonous mushrooms. This species is found all over the world, growing in coniferous forest in early spring time. Common manifestation of poisoning includes gastrointestinal symptoms which include varied degrees of liver impairment.We describe three cases: acute liver injury, acute liver failure and acute-on-chronic liver failure due to G. esculenta poisoning. At admission patients presented with encephalopathy and features of liver failure. Two of them recovered completely following supportive management while the remaining patient who also had preexisting liver disease developed multiorgan failure and subsequently died.Although a rare occurrence, G. esculenta poisoning should be considered in the differential diagnosis of acute liver failure. 相似文献
40.
心力衰竭是一种慢性疾病,是心脏无法泵出足够的血液为其他身体器官提供氧气,从而引发呼吸短促、疲劳和水肿等症状。目前其治疗包括病因治疗、一般治疗、药物治疗及非药物治疗等,其中血管紧张素受体脑啡肽酶抑制剂(ARNI)是当前新研发出的一类抗心衰药物,沙库巴曲缬沙坦是其代表药物,具有阻断肾素-血管紧张-醛固酮系统(RAAS)及抑制脑啡肽酶(NEP)的双重作用,新的欧美指南均推荐用于射血分数降低心力衰竭(HFrEF)的治疗。本文现就沙库巴曲缬沙坦在心力衰竭治疗中的作用机理、临床试验、药物安全性作一综述,旨在为该病的临床治疗提供参考。 相似文献